Aktuelle Dermatologie 2018; 44(04): 140-143
DOI: 10.1055/s-0043-124053
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Hautkrebsvorsorge PLUS − Die Früherkennung von HPV-bedingten Plattenepithelkarzinomen in der dermatologischen Praxis

Advanced Skin Cancer Screening − About the Early Detection of HPV-Related Squamous Cell Carcinoma in Dermatological Practice
R. Hilfrich
Abviris Deutschland GmbH, Ammersbek
› Author Affiliations
Further Information

Publication History

Publication Date:
02 January 2018 (online)

Zusammenfassung

Die Zahl der Neuerkrankungen an HPV-bedingten Plattenepithelkarzinomen ist stark im Anstieg begriffen. Geschlechterspezifisch sind wesentliche Unterschiede hinsichtlich der Lokalisation der Kanzerosen erkennbar. Während Frauen überwiegend von Anogenitalkarzinomen betroffen sind, erkranken Männer in erster Linie an HPV-bedingtem Mund- und Rachenkrebs. Insgesamt stellen Karzinome in Mund und Rachen mittlerweile die häufigste HPV-bedingte Tumorart in den entwickelten Ländern dar. Die Früherkennung dieser Tumoren ist maßgeblich für eine gute Prognose. Während es bislang keine aussagekräftige und praktikable Methode der Früherkennung für HPV-bedingte Tumoren im Rachen gab, stellt das neue immunologische Testverfahren unter Verwendung von Anti-HPV16 L1 DRH1 eine sinnvolle Ergänzung des Hautkrebsscreenings dar.

Abstract

The incidence of HPV-related squamous cell carcinoma is increasing rapidly. Significant gender-specific differences in the localization of the cancers are observed. While women are predominantly affected by anogenital carcinoma, men primarily develop HPV-related mouth and throat cancer. Overall, carcinomas in the mouth and throat are now the most common type of HPV-related tumors in developed countries. The early detection of these tumors is crucial for a good prognosis. While there has been no reliable and practical method of early detection of HPV-related tumors in the throat, the new immunological test procedure using anti-HPV16 L1 DRH1 is a useful adjunct to skin cancer screening.

 
  • Literatur

  • 1 de Villiers EM, Fauquet C, Broker TR. et al. Classification of papillomaviruses. Virology 2004; 324: 17-27
  • 2 Syrjänen K, Syrjänen S, Lamberg M. et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous carcinogenesis. Int J Oral Surg 1983; 12: 418-424
  • 3 CDC. https://www.cdc.gov/cancer/hpv/statistics/cases.htm (letzter Zugriff: 30. 11. 2017)
  • 4 Koliopoulos G, Nyaga VN, Santesso N. et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8: CD008587
  • 5 Krebs in Deutschland. Robert Koch-Institut; 10. Ausgabe; 2015
  • 6 Gaertner L-M. Prävalenz und klinischer Verlauf von Mundhöhlen- und Oropharynxkarzinomen von 1993 bis 2009 im Spiegel veränderter Therapie-Algorithmen. Dissertation zur Erlangung des akademischen Grades Dr. med. an der Medizinischen Fakultät der Universität Leipzig, Betreuer: Prof. Dr. med. A. Dietz, Dr. med. A. Boehm. Veröffentlichung: 14. 7. 2016; als PDF unter: http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-206871 am 30. 11. 2017.
  • 7 Termine N, Panzarella V, Falaschini S. et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988 – 2007). Ann Oncol 2008; 19: 1681-1690
  • 8 Klussmann JP, Weissenborn SJ, Wieland U. et al. Prevalence, distribution and viral load of human papillomavirus DNA in tonsillar carcinomas. Cancer 2001; 92: 2875-2884
  • 9 Kreimer AR, Clifford GM, Boyle P. et al. Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475
  • 10 Sonawane K, Suk R, Chiao EY. et al. Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Ann Intern Med 2017; 167: 714-724
  • 11 Christensen ND, Kreider JW, Cladel NM. et al. Monoclonal antibodies recognizing human papillomavirus type 11 (HPV-11) were prepared from BALB/c mice immunized with intact HPV-11 virions obtained from morphologically transformed human foreskin xenografts grown subrenally in athymic mice. Four of five monoclonal antibodies that were reactive by enzyme-linked immunosorbent. J Virol 1990; 64: 5678-5681
  • 12 Sehr P, Müller M, Höpfl R. et al. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002; 106: 61-70
  • 13 Robbins HA, Li Y, Porras C. et al. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis 2014; 14: 120
  • 14 Loewenthal M, Busch C-J, Rieckmann T. et al. Analysis of HPV-16-L1-specific antibodies and correlation with risk for oropharyngeal cancer (OPSCC) in a prospective cohort of 45.000 individuals. Oral presentation, International symposium of HPV infection in Head and Neck cancer. Nov. 3rd – 4th, 2017
  • 15 Hartwig S, Syrjänen S, Dominiak-Felden G. et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012; 12: 30
  • 16 Wagner S, Würdemann N, Wittekindt C. et al. Immune response to HPV16 L1 Distribution of serum antibodies against human papillomavirus among patients with oropharyngeal squamous cell carcinoma (OSCC). International Symposium on HPV in Head and Neck Cancer, Poznan, Poland, 2014
  • 17 Weiland T, Wolf A, Vasicek S. et al. Bestimmung des serologischen HPV16 Status im Verlauf der Therapie bei Patienten mit Oropharynxkarzinomen, Oral presentation. 61. Österreichischer HNO-Kongress, 13. – 17. September 2017, Wien
  • 18 S3-Leitlinie Prävention von Hautkrebs Version 1. 1. – 4. April 2014, AWMF-Registernummer: 032/052OL Kap. 5.1.3.1